KLP Kapitalforvaltning AS Takes Position in Twist Bioscience Co. (NASDAQ:TWST)

KLP Kapitalforvaltning AS acquired a new position in Twist Bioscience Co. (NASDAQ:TWST) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 12,100 shares of the company’s stock, valued at approximately $562,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in TWST. Wilmington Savings Fund Society FSB bought a new position in Twist Bioscience during the 3rd quarter valued at about $34,000. Van ECK Associates Corp boosted its holdings in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after purchasing an additional 267 shares during the last quarter. US Bancorp DE grew its position in Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after purchasing an additional 601 shares during the period. Beaird Harris Wealth Management LLC purchased a new stake in Twist Bioscience during the 3rd quarter valued at $95,000. Finally, KBC Group NV lifted its holdings in shares of Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after buying an additional 1,226 shares during the period.

Insider Transactions at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,726 shares of the firm’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $41.68, for a total value of $71,939.68. Following the transaction, the chief executive officer now directly owns 660,966 shares of the company’s stock, valued at approximately $27,549,062.88. This trade represents a 0.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Robert Chess sold 5,000 shares of Twist Bioscience stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $50.00, for a total value of $250,000.00. Following the completion of the sale, the director now directly owns 16,641 shares in the company, valued at $832,050. This represents a 23.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,799 shares of company stock worth $1,593,944 over the last quarter. 3.01% of the stock is currently owned by insiders.

Analyst Ratings Changes

TWST has been the subject of a number of research reports. Robert W. Baird upped their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, February 4th. JPMorgan Chase & Co. upped their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the company an “overweight” rating in a report on Monday, February 3rd. Finally, Wolfe Research started coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. According to MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and an average target price of $54.40.

Twist Bioscience Trading Down 1.9 %

NASDAQ TWST opened at $38.21 on Thursday. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90. The company has a fifty day simple moving average of $44.47 and a two-hundred day simple moving average of $45.23. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The stock has a market cap of $2.28 billion, a P/E ratio of -11.30 and a beta of 2.15.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. During the same quarter in the previous year, the firm posted ($0.75) EPS. The firm’s revenue was up 24.1% compared to the same quarter last year. On average, analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.